Medtech 100: For Edwards Lifesciences' Mike Mussallem, Inspiring People Has Been A Way Of Life

Whatever the new technology, for Mike Mussallem, it always had to start and end with the patient

Edwards Lifesciences CEO Mike Mussallem has a unique and long-standing perspective of what the medtech industry should be and do. In over two decades, he has built the structural heart disease and critical care monitoring company into one of the global medtech industry’s most effective innovators. That legacy is sure to last after his retirement as CEO in spring 2023.  

Michael Mussallem, Edwards Lifesciences CEO
• Source: Edwards Lifesciences (BEN CAMACHO)

Mike Mussallem has a long memory and a hold on detail from history as if it were yesterday. He recalls the personal dilemmas he had on deciding whether or not to close research programs – some of the “smaller” decisions a CEO must make – just as readily as how he felt during the milestone moments of Edwards Lifesciences Corp.’ evolution.

Those started in 2000, when Edwards Lifesciences Corp. was spun out from Baxter Healthcare Corp.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Company Rankings

MTI100 - Into 2025: Investor Optimism Ahead As Big Medtech Proves ‘It’s All About Value’

 
• By 

Pressure to exploit connected care functionality is accelerating the shift in care delivery away from the inpatient setting. Medtechs are reshaping to maximize faster-growth opportunities.

MTI100 - Medtech Industry Reaches New Chapter In Its Structural Evolution

The Top 100 ranking of global medtechs by revenues for 2023 illustrated how the leaders continue to tailor innovation to users and patients according to market trends while driving portfolio management for growth.

Medtech Insight’s Latest Medtech 100 Ranking Published

 
• By 

Top 100 publicly listed medtech companies ranked by global revenues, and listings for the top cardiology, orthopedic, IVD and imaging performers based on 2023 or 2023-24 revenues, are now available from Medtech Insight.

More from Market Intelligence

Prostate Cancer Research Urges UK To Implement Screening Program Without Delay

 

Implementing a reflex test alongside traditional prostate cancer screening is cost-effective for high-risk groups, claims Prostate Cancer Research. Oxford BioDynamics sheds light on UK market conditions influencing the adoption of its reflex test, EpiSwitch PSE.

Philips Partners With Three Health Insurance Providers To Remotely Monitor High-Risk Pregnancies

 

Several counties in the US state of Georgia are maternity care “deserts.” Remote monitoring of high-risk pregnancies with maternal hypertension and diabetes could help improve the state’s high rate of maternal mortality, according to leading health service provider Philips.

Medtronic Widens Parkinson’s aDBS Opportunity With Key US Approvals

 

Medtronic’s US FDA approval for BrainSense aDBS and BrainSense EI software features of the Percept neurostimulator device has quickly followed CE marking in January.